PAVmed End Period Cash Flow vs Free Cash Flow Analysis

PAVMZ Stock

USD 0.01 0.01 40.94%

PAVmed Series financial indicator trend analysis is much more than just breaking down PAVmed Series Z prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PAVmed Series Z is a good investment. Please check the relationship between PAVmed Series End Period Cash Flow and its Free Cash Flow accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Series Z. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

End Period Cash Flow vs Free Cash Flow

End Period Cash Flow vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PAVmed Series Z End Period Cash Flow account and Free Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between PAVmed Series' End Period Cash Flow and Free Cash Flow is -0.72. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of PAVmed Series Z, assuming nothing else is changed. The correlation between historical values of PAVmed Series' End Period Cash Flow and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of PAVmed Series Z are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of End Period Cash Flow i.e., PAVmed Series' End Period Cash Flow and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.72

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

End Period Cash Flow

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from PAVmed Series' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PAVmed Series Z current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Series Z. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

At this time, PAVmed Series' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 29.4 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 11.99 in 2024.

PAVmed Series fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Total Equity	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Common Stock Shares Outstanding	Non Current Liabilities Total	Property Plant And Equipment Net	Property Plant And Equipment Gross	Property Plant Equipment	Short Long Term Debt Total	Long Term Debt
Total Assets		0.28	0.46	0.3	-0.58	-0.66	0.99	0.99	-0.59	0.75	-0.1	0.79	0.45	1.0	0.79	0.78	0.66	0.62	-0.55	-0.54	0.78	0.55	0.52	0.7	0.75	-0.66
Other Current Liab	0.28		0.36	-0.27	0.07	-0.44	0.24	0.24	-0.01	0.16	0.03	0.43	0.37	0.25	-0.16	-0.03	0.53	0.17	-0.12	0.1	0.19	0.56	0.56	0.15	0.46	-0.11
Total Current Liabilities	0.46	0.36		-0.69	0.44	-0.97	0.37	0.37	-0.54	0.86	-0.03	0.9	1.0	0.4	0.21	0.57	0.91	0.74	-0.61	-0.47	-0.08	0.95	0.96	0.81	0.91	-0.73
Total Stockholder Equity	0.3	-0.27	-0.69		-0.94	0.51	0.41	0.41	0.12	-0.28	0.0	-0.32	-0.7	0.38	0.47	0.1	-0.47	-0.28	0.16	0.02	0.7	-0.61	-0.64	-0.26	-0.38	0.18
Net Debt	-0.58	0.07	0.44	-0.94		-0.22	-0.67	-0.67	0.08	0.0	0.04	0.01	0.45	-0.65	-0.6	-0.31	0.18	0.07	0.04	0.13	-0.89	0.33	0.36	0.01	0.06	0.04
Retained Earnings	-0.66	-0.44	-0.97	0.51	-0.22		-0.58	-0.58	0.63	-0.92	0.06	-0.98	-0.97	-0.6	-0.35	-0.66	-0.96	-0.77	0.64	0.55	-0.16	-0.96	-0.96	-0.86	-0.98	0.76
Cash	0.99	0.24	0.37	0.41	-0.67	-0.58		1.0	-0.55	0.7	-0.09	0.73	0.36	1.0	0.8	0.77	0.58	0.55	-0.52	-0.52	0.85	0.45	0.42	0.65	0.69	-0.63
Cash And Short Term Investments	0.99	0.24	0.37	0.41	-0.67	-0.58	1.0		-0.55	0.7	-0.09	0.73	0.36	1.0	0.8	0.77	0.58	0.55	-0.52	-0.52	0.85	0.45	0.42	0.65	0.69	-0.63
Common Stock Total Equity	-0.59	-0.01	-0.54	0.12	0.08	0.63	-0.55	-0.55		-0.59	0.53	-0.67	-0.54	-0.56	-0.34	-0.33	-0.67	-0.42	0.13	0.49	-0.3	-0.63	-0.62	-0.52	-0.67	0.24
Capital Surpluse	0.75	0.16	0.86	-0.28	0.0	-0.92	0.7	0.7	-0.59		0.06	0.94	0.86	0.72	0.57	0.88	0.81	0.77	-0.78	-0.69	0.32	0.79	0.78	0.96	0.92	-0.91
Other Current Assets	-0.1	0.03	-0.03	0.0	0.04	0.06	-0.09	-0.09	0.53	0.06		-0.07	-0.03	-0.09	0.11	0.25	-0.13	0.11	-0.23	-0.45	-0.07	-0.15	-0.14	0.29	-0.1	-0.28
Other Stockholder Equity	0.79	0.43	0.9	-0.32	0.01	-0.98	0.73	0.73	-0.67	0.94	-0.07		0.9	0.75	0.48	0.74	0.94	0.76	-0.66	-0.59	0.35	0.92	0.91	0.89	0.99	-0.79
Total Liab	0.45	0.37	1.0	-0.7	0.45	-0.97	0.36	0.36	-0.54	0.86	-0.03	0.9		0.39	0.2	0.56	0.91	0.73	-0.61	-0.47	-0.09	0.95	0.96	0.8	0.91	-0.72
Total Current Assets	1.0	0.25	0.4	0.38	-0.65	-0.6	1.0	1.0	-0.56	0.72	-0.09	0.75	0.39		0.79	0.78	0.6	0.57	-0.53	-0.53	0.83	0.48	0.45	0.67	0.71	-0.64
Common Stock	0.79	-0.16	0.21	0.47	-0.6	-0.35	0.8	0.8	-0.34	0.57	0.11	0.48	0.2	0.79		0.8	0.37	0.53	-0.52	-0.57	0.54	0.21	0.17	0.57	0.39	-0.61
Accounts Payable	0.78	-0.03	0.57	0.1	-0.31	-0.66	0.77	0.77	-0.33	0.88	0.25	0.74	0.56	0.78	0.8		0.54	0.64	-0.86	-0.68	0.47	0.46	0.44	0.86	0.68	-0.92
Non Current Assets Total	0.66	0.53	0.91	-0.47	0.18	-0.96	0.58	0.58	-0.67	0.81	-0.13	0.94	0.91	0.6	0.37	0.54		0.74	-0.49	-0.49	0.14	0.98	0.97	0.77	0.94	-0.63
Non Currrent Assets Other	0.62	0.17	0.74	-0.28	0.07	-0.77	0.55	0.55	-0.42	0.77	0.11	0.76	0.73	0.57	0.53	0.64	0.74		-0.42	-0.5	0.14	0.7	0.68	0.77	0.75	-0.81
Other Assets	-0.55	-0.12	-0.61	0.16	0.04	0.64	-0.52	-0.52	0.13	-0.78	-0.23	-0.66	-0.61	-0.53	-0.52	-0.86	-0.49	-0.42		0.46	-0.23	-0.48	-0.47	-0.71	-0.62	0.81
Common Stock Shares Outstanding	-0.54	0.1	-0.47	0.02	0.13	0.55	-0.52	-0.52	0.49	-0.69	-0.45	-0.59	-0.47	-0.53	-0.57	-0.68	-0.49	-0.5	0.46		-0.29	-0.41	-0.4	-0.84	-0.54	0.56
Non Current Liabilities Total	0.78	0.19	-0.08	0.7	-0.89	-0.16	0.85	0.85	-0.3	0.32	-0.07	0.35	-0.09	0.83	0.54	0.47	0.14	0.14	-0.23	-0.29		0.03	0.01	0.29	0.33	-0.28
Property Plant And Equipment Net	0.55	0.56	0.95	-0.61	0.33	-0.96	0.45	0.45	-0.63	0.79	-0.15	0.92	0.95	0.48	0.21	0.46	0.98	0.7	-0.48	-0.41	0.03		1.0	0.73	0.93	-0.6
Property Plant And Equipment Gross	0.52	0.56	0.96	-0.64	0.36	-0.96	0.42	0.42	-0.62	0.78	-0.14	0.91	0.96	0.45	0.17	0.44	0.97	0.68	-0.47	-0.4	0.01	1.0		0.72	0.93	-0.59
Property Plant Equipment	0.7	0.15	0.81	-0.26	0.01	-0.86	0.65	0.65	-0.52	0.96	0.29	0.89	0.8	0.67	0.57	0.86	0.77	0.77	-0.71	-0.84	0.29	0.73	0.72		0.86	-0.88
Short Long Term Debt Total	0.75	0.46	0.91	-0.38	0.06	-0.98	0.69	0.69	-0.67	0.92	-0.1	0.99	0.91	0.71	0.39	0.68	0.94	0.75	-0.62	-0.54	0.33	0.93	0.93	0.86		-0.76
Long Term Debt	-0.66	-0.11	-0.73	0.18	0.04	0.76	-0.63	-0.63	0.24	-0.91	-0.28	-0.79	-0.72	-0.64	-0.61	-0.92	-0.63	-0.81	0.81	0.56	-0.28	-0.6	-0.59	-0.88	-0.76

Click cells to compare fundamentals

PAVmed Series Account Relationship Matchups

PAVmed Series fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.2M	19.8M	87.0M	54.0M	33.1M	23.6M
Other Current Liab	1.4M	(15.0M)	4.3M	3.7M	6.6M	7.0M
Total Current Liabilities	11.9M	20.0M	7.6M	41.2M	54.2M	56.9M
Total Stockholder Equity	(3.8M)	1.9M	61.7M	(9.7M)	(53.8M)	(51.1M)
Net Debt	1.9M	(2.3M)	(77.3M)	(3.1M)	29.1M	30.5M
Retained Earnings	(53.7M)	(88.3M)	(138.9M)	(228.2M)	(294.4M)	(279.7M)
Cash	6.2M	17.3M	77.3M	39.7M	19.6M	18.9M
Cash And Short Term Investments	6.2M	17.3M	77.3M	39.7M	19.6M	18.9M
Liabilities And Stockholders Equity	7.2M	19.8M	87.0M	54.0M	33.1M	23.6M
Capital Surpluse	14.0M	32.6M	47.6M	87.6M	100.7M	105.7M
Other Current Assets	328.3B	1.7M	5.2M	3.9M	3.8M	3.6M
Other Stockholder Equity	47.6M	87.6M	198.1M	215.9M	237.6M	249.5M
Total Liab	11.9M	20.3M	7.6M	43.0M	57.1M	60.0M
Total Current Assets	6.5M	18.9M	82.6M	43.9M	24.5M	20.8M
Common Stock	40.5K	64K	86K	95K	9K	8.6K
Accounts Payable	2.4M	3.0M	3.3M	2.7M	1.8M	2.1M
Non Current Assets Total	692.9K	837K	4.3M	10.1M	8.6M	9.1M
Common Stock Shares Outstanding	2.0M	3.2M	5.2M	5.9M	7.2M	7.6M
Non Current Liabilities Total	10.5M	300K	4.3B	1.8M	3.0M	2.8M
Short Long Term Debt Total	7.9M	8.1M	15.0M	36.6M	48.7M	51.2M
Net Invested Capital	2.0M	14.3M	59.2M	21.3M	(12.6M)	(12.0M)
Net Working Capital	(5.3M)	(1.0M)	75.1M	2.7M	(29.7M)	(28.2M)
Capital Stock	2.3M	2.6M	2.5M	2.8M	3.0M	2.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for PAVmed Stock Analysis

When running PAVmed Series' price analysis, check to measure PAVmed Series' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PAVmed Series is operating at the current time. Most of PAVmed Series' value examination focuses on studying past and present price action to predict the probability of PAVmed Series' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PAVmed Series' price. Additionally, you may evaluate how the addition of PAVmed Series to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

PAVmed End Period Cash Flow vs Free Cash Flow Analysis

End Period Cash Flow vs Free Cash Flow

End Period Cash Flow vs Free Cash Flow Correlation Analysis

Correlation Coefficient

End Period Cash Flow

Free Cash Flow

PAVmed Series fundamental ratios Correlations

PAVmed Series Account Relationship Matchups

High Positive Relationship

High Negative Relationship

PAVmed Series fundamental ratios Accounts

Also Currently Popular

Additional Tools for PAVmed Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Short Long Term Debt Total	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Total Liab	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Property Plant And Equipment Gross	- 0.96	Retained Earnings
Property Plant And Equipment Net	- 0.96	Retained Earnings